Individual investors responded to the market selloff earlier this week triggered by concerns regarding a Chinese artificial ...

Geode Capital Management LLC’s holdings in Vanda Pharmaceuticals were worth $6,689,000 as of its most recent SEC filing. Several other large investors have also bought and sold shares of VNDA.

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a ...

A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...

"Retail investors have (so far) responded to the DeepSeek-induced equity sell-off by doing what they do best: buying the dip." That's from Vanda Research's new bulletin analyzing the trading of ...

After Vanda Pharmaceuticals’ phase 3 miss and FDA rejection for its stomach disorder candidate, CEO Mihael Polymeropoulos, M.D., is calling out the regulatory agency for a “disturbing pattern ...

WASHINGTON, Jan. 8, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. Vanda Logo (PRNewsfoto/Vanda ...

With an impressive ROE of -0.98%, the company showcases effective utilization of equity capital. Return on Assets (ROA): Vanda Pharma's ROA surpasses industry standards, highlighting the company's ...